financetom
TNDM
financetom
/
Healthcare
/
TNDM
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Tandem Diabetes Care, Inc.TNDM
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
1.12B
Revenue (ttm)
940.20M
Net Income (ttm)
-96.03M
Shares Out
66.47M
EPS (ttm)
-1.47
PE Ratio
n/a
Forward PE
n/a
Dividend
n/a
Ex-Dividend Date
n/a
Volume
442,811
Open
17.10
Previous Close
17.04
Day's Range
16.57 - 17.25
52-Week Range
15.75 - 53.69
Beta
1.53
Analysts
Buy
Price Target
44.44 (+163.04%)
Earnings Date
Apr 30, 2025
Description >

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally.

The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software.

In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin.

It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008.

Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Latest News >
Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial
Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial
Jun 6, 2024
08:39 AM EDT, 06/06/2024 (MT Newswires) -- Sagimet Biosciences ( SGMT ) said Thursday that additional data from a phase 2b trial of denifanstat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis, or MASH, showed that the study met the primary and secondary endpoints. Denifanstat, an oral daily pill, achieved statistically significant results on primary and secondary liver biopsy endpoints in...
Monster Beverage Reports Preliminary Results of Common Shares Tender Offer
Monster Beverage Reports Preliminary Results of Common Shares Tender Offer
Jun 6, 2024
08:39 AM EDT, 06/06/2024 (MT Newswires) -- Monster Beverage ( MNST ) said Thursday a total of about 77.4 million of its common shares were validly tendered and not validly withdrawn at $53 apiece under its modified Dutch auction tender offer. Additionally, under notice of guaranteed delivery, roughly 41.6 million of the company's shares were tendered, Monster Beverage ( MNST...
Vista Outdoor Surges As MNC Capital Ups The Ante With Sweetened Bid: Details
Vista Outdoor Surges As MNC Capital Ups The Ante With Sweetened Bid: Details
Jun 6, 2024
Vista Outdoor Inc. ( VSTO ) shares are trading higher after MNC Capital increased its offer to acquire the company for over $3.0 billion. The revised proposal of $39.50 represents a 46% premium to the VWAP from the announcement of Vista’s transaction with the Czechoslovak Group a.s. on October 16, 2023, up to the last closing price before MNC’s initial...
Dolby Labs to acquire GE Licensing in $429 million deal
Dolby Labs to acquire GE Licensing in $429 million deal
Jun 6, 2024
June 6 (Reuters) - Dolby Laboratories ( DLB ) said on Thursday it would acquire GE Licensing, an intellectual property licensing business primarily targeting the consumer digital media and electronics sectors, in a $429 million deal. ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved